** U.S.-listed shares of German drugmaker CureVac 5CV.DE, CVAC.O rise 15.4% to $3.23 premarket
** European Patent Office upheld a CVAC mRNA patent after it was challenged by rival BioNTech 22UAy.DE, co said on Thursday
** A German court will decide on July 1 if BioNTech infringed this patent
** The dispute is part of a larger ongoing patent battle between CureVac and BioNTech over mRNA tech used in COVID-19 vaccines
** CVAC fell 8.2% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。